Table 1. Baseline characteristics of 14 enrolled gemcitabine-refractory patients.

Characteristic	Frequency
	Number	Percent
Age, years
Median	64
Range	51–76
Gender
Male	8	58
Female	6	42
ECOG Performance Status
0	6	43
1	7	50
2	1	7
Race
Caucasian	13	93
African American	0	0
Asian	0	0
Unknown	1	7
Prior Therapya
Gemcitabine	13	93
5-Fluorouracil	2	14
Capecitabine	1	7
Radiotherapy	4	27
Surgery	8	57
Investigational	0	0
None	0	0
Prior Chemotherapy Regimensb
0	1	7
1	11	79
2	1	7
3	1	7
Metastatic sites
Liver	9	64
Abdomen/peritoneal	2	14
Lung	3	21

ECOG Eastern Cooperative Cancer Group

^aPatients appear more than once in this category

^bIncludes investigational regimens